henhaobio
Sign in

bioRxivPharmacology & ToxicologyPreprint

Pharmacokinetics of Orally Administered GS-441524 in Dogs

V. C. Yan, C.-D. Pham, M. J. Yan, A. J. Yan, S. Khadka, K. Arthur, J. J. Ackroyd, D. K. Georgiou, L. E. Roon, L. R. Bushman, P. L. Anderson, C. Li, F. L. Muller

PDFDOI

Abstract

Despite being FDA-approved for COVID-19, the clinical efficacy of remdesivir (Veklury(R)) remains contentious. We previously pointed out pharmacokinetic, pharmacodynamic and toxicology reasons for why its parent nucleoside GS-441524, is better suited for COVID-19 treatment. Here, we assess the oral bioavailability of GS-441524 in beagle dogs and show that plasma concentrations [~]24-fold higher than the EC50 against SARS-CoV-2 are easily and safely sustained. These data support translation of GS-441524 as an oral agent for COVID-19.

Reproducibility ledger

Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.

Sign in to file a reproducibility report.